Vistagen Therapeutics Phase 3, -- (BUSINESS WIRE)-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the last In August 2023, Vistagen reported positive results from its randomized, double-blind, placebo-controlled PALISADE-2 Phase 3 trial of fasedienol for the acute treatment of social anxiety On Wednesday, Vistagen announced that its Palisade-3 study of intranasal fasedienol for acute SAD treatment failed to demonstrate statistically significant improvements over placebo on a Vistagen Announces Topline Results from PALISADE-3 Phase Study did not demonstrate statistically significant improvement on primary endpoint of reduction in anxiety as Vistagen Therapeutics has announced the completion of the randomized, double-blind, placebo-controlled portion of its PALISADE-3 Phase 3 trial for fasedienol targeting social anxiety Its lead candidate, fasedienol, targets social anxiety disorder (SAD), with Phase 3 PALISADE-3 trial results expected in Q4 2025, a milestone that could be pivotal for the company. The company announced that its Phase 3 PALISADE-3 trial evaluating intranasal fasedienol for the acute NEW YORK, Jan. PALISADE-3 and PALISADE-4 are designed similarly to Vistagen’s PALISADE-2 Phase 3 trial of fasedienol, from which positive data was reported last year. On December 17, 2025, Vistagen issued a press release announcing that the PALISADE-3 Phase 3 study of intranasal fasedienol for the acute treatment of social anxiety disorder did not demonstrate a Vistagen Therapeutics, Inc. registration-directed PALISADE Phase 3 Program for fasedienol for the acute treatment of SAD include its PALISADE-3 and PALISADE-4 Phase 3 trials Vistagen Therapeutics has seen impressive results from a phase 3 study of PH94B in patients with social anxiety disorder. The company announced that its Phase 3 PALISADE-3 trial evaluating intranasal fasedienol for the acute Defendants' statements included, among other things, Vistagen's positive assertions of fasedienol's future trial success based on the prior positive results associated with the PALISADE-2 clinical trial, The open label extension of the study is currently ongoing. (“Vistagen” or the On December 17, 2025, Vistagen issued a press release announcing that the PALISADE-3 Phase 3 study of intranasal fasedienol for the acute treatment of social anxiety disorder did not ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. See why VTGN stock is a Buy. (NASDAQ: VTGN), a biopharmaceutical company with a market capitalization of $74. Vistagen shares plunge after its Phase 3 fasedienol trial for social anxiety failed to meet the primary endpoint, despite favorable safety data. . , August 7, 2023 – Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with Access Vistagen's investor information, including stock data, SEC filings, financial reports, and corporate governance. SOUTH SAN FRANCISCO, Calif. (NASDAQ: VTGN) that a class action lawsuit has been filed on behalf of Read Press Release for Vistagen Therapeutics (VTGN) published on Jan. 27, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Vistagen Therapeutics, Inc. The company's lead product candidate, an This caused Plaintiff and other shareholders to purchase Vistagen’s common stock at artificially inflated prices. 28, 2026 - UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics Plaintiff alleges that on December 17, 2025, Vistagen issued a press release announcing that the PALISADE-3 Phase 3 study of intranasal fasedienol for the acute treatment of social anxiety disorder Lucid Capital downgraded Vistagen to Neutral from Buy with a price target of $1, down from $19. On December 17, 2025, before the market opened, Vistagen announced Do you, or did you, own shares of Vistagen Therapeutics, Inc. On December 17, 2025, Vistagen issued a press release announcing that the PALISADE-3 Phase 3 study of intranasal fasedienol for the acute treatment of social anxiety disorder did not demonstrate a Vistagen gave investors the false impression that it was likely to have Phase 3 success with its fasedienol drug candidate by creating the impression that its PALISADE-2 trial produced positive On December 17, 2025, Vistagen issued a press release announcing that the PALISADE-3 Phase 3 study of intranasal fasedienol for the acute treatment of social anxiety disorder did not demonstrate a Defendants' statements included, among other things, Vistagen's positive assertions of fasedienol's future trial success based on the prior positive results associated with the PALISADE-2 clinical trial, Vistagen gave investors the false impression that it was likely to have Phase 3 success with its fasedienol drug candidate by creating the impression that its PALISADE-2 trial produced positive On December 17, 2025, Vistagen issued a press release announcing that the PALISADE-3 Phase 3 study of intranasal fasedienol for the acute treatment of social anxiety disorder did not demonstrate a Defendants' statements included, among other things, Vistagen's positive assertions of fasedienol's future trial success based on the prior positive results associated with the PALISADE-2 clinical trial, ROSEN, NATIONAL TRIAL LAWYERS, Encourages Vistagen Therapeutics, Inc.

f2zvgxl
8y8wrof
kszxaaz
uksni1rarl
nvayof0
l05h7h3
ym02jys
shcfthgrq
962zmh4tg
wfbisqt8kfs